Boehringer Ingelheim

United States Pet Medication Market Insights Report 2024-2029 Featuring Prominent Vendors - Boehringer Ingelheim, Ceva, Elanco Animal Health, Merck, Zoetis, Bayer AG, and Novartis - ResearchAndMarkets.com

Retrieved on: 
水曜日, 4月 17, 2024
Pharmaceutical, Health, Veterinary, USD, Vaccination, Inflammation, Bayer, Nonsteroidal anti-inflammatory drug, Boehringer Ingelheim, Pet, Parasitism, Animal, Insurance, Zoonosis, Urbanization, Tick, Prescription, Cat, Human, Novartis, Family, Pain management, Food, Anesthetic, Dog, Merck, Growth, Prevalence, Medical imaging

The U.S. pet medication market report contains exclusive data on 39 vendors.

Key Points: 
  • The U.S. pet medication market report contains exclusive data on 39 vendors.
  • The competition in the U.S. pet medication market is intense, with several global players offering diverse products.
  • Currently, Ceva, Zoetis, Boehringer Ingelheim, Merck, Elanco, Bayer AG, and Novartis are the leading vendors in pet medication production and distribution in the U.S.
  • The prescription medications segment occupies a significant market share of over 53% in the U.S. pet medication market.

Sage Veterinary Imaging Welcomes New President

Retrieved on: 
木曜日, 4月 25, 2024
University, CFO, American College, ACVR, Boehringer Ingelheim, Purdue University, SVI, Business school, Business, Patient, Health, Therapy

ROUND ROCK, Texas, April 25, 2024 /PRNewswire/ -- Sage Veterinary Imaging (SVI) has welcomed Peter Selover to its team as president and chief operating officer. Selover had previously served as chief executive officer of Exubrion Therapeutics.

Key Points: 
  • ROUND ROCK, Texas, April 25, 2024 /PRNewswire/ -- Sage Veterinary Imaging (SVI) has welcomed Peter Selover to its team as president and chief operating officer.
  • SVI founder, Dr. Jaime Sage, will maintain her role in providing the highest quality veterinary imaging to referring veterinarians and their clients.
  • In addition to the three Sage Veterinary Imaging centers in Texas and Utah, SVI is one of only 25 residency programs accredited by the American College of Veterinary Radiology (ACVR) as a teaching hospital.
  • "Dr. Sage and her team are meeting the growing need for higher quality veterinary imaging.

Canaan Adds Accomplished Executive and Scientist, Uwe Schoenbeck, Ph.D., Along with New Capital, to Bolster its Biopharma Investment Efforts

Retrieved on: 
水曜日, 4月 17, 2024
Investment, Cell biology, Boehringer Ingelheim, News, Hospital, Abstract, Cardiology, CTI, WRDM, Partnership, Research, Brigham, Development, Cardiovascular Research, Therapy, Brigham and Women's Hospital, Senior, Science, Translation, Inflammatory bowel disease, Patient, Neurology, Acquisition, Initial public offering, General partnership, Metabolism, Harvard Medical School, Health, Assistant, Emerging, Biotechnology, Pharmaceutical industry

MENLO PARK, Calif., April 17, 2024 /PRNewswire/ -- Canaan, a venture capital firm that invests in entrepreneurs with visionary ideas, announced the addition of Uwe Schoenbeck, Ph.D., to its healthcare investment team as a new Venture Partner. Dr. Schoenbeck's impressive career has spanned more than 25 years in the life science and healthcare industry, as well as academia, providing him with an exceptional global network among leading research institutions, biotechnology and biopharmaceutical companies, and venture firms. He is highly regarded for his contributions in enabling and translating emerging science into breakthrough therapies, reaching from scientific collaborations, licensing, and acquisition deals to venture investing. In joining Canaan's healthcare investment team, Dr. Schoenbeck will help drive new investments and company creation from Canaan XIII, the firm's latest fund, by bringing in deep scientific and pharmaceutical perspectives, while also serving as a valuable resource to companies across the firm's existing biopharma portfolio. To this end, he has already facilitated his first investment as a member of the team, leading Canaan's participation in the recently announced $132 million Series B financing for Alterome Therapeutics and being named a member of the company's board of directors.

Key Points: 
  • Most recently, Dr. Schoenbeck served as Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I) in Pfizer's Worldwide Research, Development & Medical (WRDM) division.
  • In leading ES&I, he worked to harness external breakthrough science, assets, and technologies by leveraging a broad range of partnering vehicles.
  • "It is not often that we have the opportunity to add someone of Uwe's caliber and track record to the Canaan investment team.
  • In additional news, Canaan today reported that it has expanded the size of its biopharma investment funds with the addition of more than $100 million in new capital.

Greater Good Charities and Boehringer Ingelheim Kick Off Fourth Year of Good Flights Program and Celebrate Successful Transport of More Than 12,800 Shelter Pets to Adoptive Homes Including Nearly 1,300 Asymptomatic Heartworm-Positive Dogs

Retrieved on: 
月曜日, 4月 8, 2024
DSM-IV codes, PLUS, Transport, Disease, Moxidectin, Seizure, Boehringer Ingelheim, Tablet, Diarrhea, Life, House, Dog, Lethargy, Euthanasia, Greater good, Coccidioides immitis, Safety, Terrebonne Parish, Louisiana, Good, Hookworm, Pet, Cat, Atmosphere of Earth, Itch, Animal rescue, Vomiting, Flea, Heart, Boehringer Ingelheim Animal Health, Pharmaceutical industry

To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.

Key Points: 
  • To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.
  • Air and ground transports for Good Flights occur approximately five times a month and many have Save a Heart pets on them.
  • “The Good Flights Program and Save a Heart initiative represents a remarkable collaboration between Greater Good Charities and Boehringer Ingelheim,” said Dr. Julie Ryan-Johnson, Senior Associate Director - Shelter Engagement Program, Boehringer Ingelheim.
  • Good Flights covers transport costs, provides mentorship, pharmaceuticals, and furnishes much needed supplies including pet crates, bowls, and leashes.

AAFA's Advocacy for Health Equity Leads to White House Address on Asthma Inhaler Pricing

Retrieved on: 
水曜日, 4月 3, 2024
AAFA, Conditional sentence, AstraZeneca, Health equity, Part, GSK, Boehringer Ingelheim, Patient, Asthma, Medicare (United States), Medicaid, Medicare, Inflation, Government

The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.

Key Points: 
  • The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.
  • “On behalf of the 27 million people in the United States with asthma, we appreciate the leadership of President Biden and Senator Sanders to bring down costs for asthma treatments.
  • Pricing announcements made in March by some manufacturers of inhalers will mean lower costs and improved access to asthma medicine for many people with asthma starting this June,” stated Mendez.
  • “Lower out-of-pocket costs have the potential to drastically improve asthma health outcomes.

Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
木曜日, 3月 28, 2024
Research, Fulvestrant, NMPA, AstraZeneca, Disease, Progression-free survival, CDX, Boehringer Ingelheim, Patient, Webcast, NGS, Hospital, Breast, Breakthrough, Safety, HR, Depreciation, ID, Precision, Food, Marketing, FDA, Cryptocurrency

Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.

Key Points: 
  • Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.
  • Total value of new contracts entered into during 2023 amounted to RMB310 million, representing a 24% increase from 2022.
  • Revenues were RMB121.1 million (US$17.1 million) for the three months ended December 31, 2023, representing a 14.9% decrease from RMB142.2 million for the same period in 2022.
  • Burning Rock will host a conference call to discuss the fourth quarter and full year 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on March 29, 2024.

SPEVIGO® approved for expanded indications in China and the US

Retrieved on: 
火曜日, 3月 19, 2024
Arthralgia, Urinary tract infection, Uncertainty, Human, NMPA, Psoriasis, Disease, Multiple organ dysfunction syndrome, Incidence, Risk, GPP, Boehringer Ingelheim, Patient, Ageing, Executive officer, Immunoglobulin G, Anxiety, Doctor of Philosophy, MD, Quality of life, Flare, Injection site reaction, Clinical trial, Skin, Fever, Immune system, Pain, Itch, Food, FDA, Yale University, Fear

In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.

Key Points: 
  • In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.
  • “Until now, people living with GPP have not had any approved options to treat their disease,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, Yale University and Central Connecticut Dermatology.
  • “Experiencing GPP can be mentally and physically devastating, leaving those affected with uncertainty and fear of the next episode.
  • Therefore, expanding the treatment of GPP is a critical step towards addressing patients’ needs.”

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
月曜日, 3月 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Against Kidney Disease

Retrieved on: 
金曜日, 3月 15, 2024
American Kidney Fund, Candid (organization), Disease, Caregiver, Vertex Pharmaceuticals, Risk, GSK, Boehringer Ingelheim, GSK plc, Kidney disease, AKF, Therapy, Kidney, Eli Lilly and Company, Platinum, Charity Navigator, Corporation, Pharmaceutical industry

ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program .

Key Points: 
  • ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program .
  • Corporate Members provide essential support to AKF as it continues its fight against kidney disease on all fronts—from prevention through post-transplant living.
  • “Our Corporate Members—both new and returning—help make the work AKF does for the kidney community possible,” said LaVarne A. Burton, AKF President and CEO.
  • Corporate Members fund AKF’s essential work, including:
    Award-winning, evidence-based kidney health education resources that reach millions of people living with kidney disease, caregivers, living organ donors and health care providers each year
    The Corporate Membership Program is open to institutional partners that support AKF’s mission of fighting kidney disease and helping people live healthier lives.

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Retrieved on: 
火曜日, 3月 12, 2024
Research, Internal medicine, Overweight, Weill Cornell Medicine, The Obesity Society, Facial muscles, Obesity, Weight loss, SARM, Enobosarm, Education, Flyte, Metabolism, Patient, Weight, Pfizer, Obesity medicine, Davidoff, MD, Weill Cornell Medical Center, Jacobi Medical Center, Eli Lilly and Company, Bangladesh Technical Education Board, MOVE, Boehringer Ingelheim, Directory, Pharmaceutical industry

He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.

Key Points: 
  • He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.
  • Weight loss through any modality produces muscle loss, and there is an unmet need to minimize that in certain groups of patients in order to produce better quality weight loss.
  • In conjunction with a GLP-1 drug, enobosarm has the potential to deliver better quality weight loss while utilizing lower doses of the GLP-1 drug.
  • We are fortunate that Dr. Aronne and the other senior expert members of our Scientific Advisory Board will help guide the enobosarm development program.”